EMD Emyria Limited
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Subiaco, Australia.
Returns
| 1 day | 0.0% |
| 1 week | -10.0% |
| 1 month | 0.0% |
| 3 months | 9.8% |
| 6 months | -8.2% |
| 1 year | -29.7% |
| 3 years | -35.7% |
Risk
| Volatility (1y ann.) | 75.5% |
| Beta vs ASX 200 | 0.96 |
| Sharpe (1y) | -0.16 |
| VaR 95% (1-day) | -6.1% |
| Max drawdown (1y) | -51.4% |
| Off 1-year high | -39.2% |
Technicals
| RSI(14) | 46 |
| vs 50DMA | -4.5% |
| vs 200DMA | -6.0% |
| Trend | Death cross |
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
- Revenue—
- Gross profit—
- Operating income—
- Net income—
- Diluted EPS-0.01
- Free cash flow—
- Net debt—